Dr. Claudia Sevilla, MD

Dr. Sevilla practices at Sharp Rees-Stealy Medical Group, Inc in San Diego, California.

Dr. Sevilla's NPI, 1689081275, was assigned on July 16, 2014. Dr. Sevilla graduated from David Geffen School of Medicine at UCLA in 2012. Dr. Sevilla holds California license A131270.

Dr. Sevilla's primary practice is Sharp Rees-Stealy Medical Group, Inc, at 5651 Copley Dr, San Diego, CA 92111 in San Diego County. The practice phone is (858) 262-6666.

Dr. Sevilla's primary practice is Sharp Rees-Stealy Medical Group, Inc in San Diego, California. Dr. Sevilla is also affiliated with Sharp Memorial Hospital. The medical group on file is Emergency and Acute Care Medical Corporation. Dmand AI also links Dr. Sevilla to 3 more hospitals, 4 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sevilla practices, 8 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Sevilla's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Sevilla is board certified in female pelvic medicine and reconstructive surgery by the American Board of Urology. Dr. Sevilla is licensed in California.

Dmand AI lists bladder disease, enlarged prostate, kidney removal surgery, kidney stone disease, pelvic prolapse, urinary endoscopy, urine flow blockage and UTI among the conditions Dr. Sevilla treats.

CMS data shows 309 Medicare services from Dr. Sevilla across 6 procedure codes in 2024, for 138 Medicare patients. Medicare paid $13,112 for them. Every service was in an office.

CMS counts 138 Medicare patients who saw Dr. Sevilla in 2024. The largest group is 75 to 84, with 56 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 44% are also on Medicaid. Their average risk score is 1.42, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Sevilla's median patient age at 68, with 90% women.

In 2024, Dr. Sevilla wrote 2,226 Medicare Part D claims for 541 patients. 52% of them were for generic drugs. CMS names the drug for 2,152 of them, across 21 drugs with 11 or more claims each, at $730,872 in total drug cost. In 2023, CMS named 2,704 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Sevilla for performance year 2024, reported as part of a group. Dr. Sevilla accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sevilla as offering telehealth.

Dmand AI links 4 papers to Dr. Sevilla. Dr. Sevilla's most frequent co-authors are Alexandriah Nicole Alas, MD, Biatris A. Barrera, MD and Stephanie Chu, MD.

CMS Open Payments shows 220 general payments to Dr. Sevilla from 30 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 85% of the total. Medtronic USA, Inc. paid the most, $1,566.

Dr. Sevilla graduated from David Geffen School of Medicine at UCLA in 2012.

Dr. Sevilla is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.